Related Experiment Video

Updated: May 17, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape

François Ghiringhelli1, Mélanie Bruchard, Fanny Chalmin

  • 1INSERM U866, Faculté de Médecine, Université de Bourgogne, Dijon, France. fghiringhelli@cgfl.fr

Journal of Biomedicine & Biotechnology
|November 8, 2012
PubMed

Insights

Tumor cells evade immune responses by producing adenosine, which suppresses T cells. Inhibiting enzymes like CD73 and CD39 that create adenosine can restore anti-cancer immunity and improve therapies.

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • Tumor immunosurveillance is crucial for controlling cancer growth.
  • Cancer cells employ mechanisms to evade the immune response.
  • Adenosine, generated in the tumor microenvironment, suppresses anti-tumor T cell activity.

Purpose of the Study:

  • To explore the role of adenosine and ectonucleotidases in immune evasion.
  • To highlight the impact of adenosine generation on the anti-tumor immune response.
  • To discuss targeting ectonucleotidases for cancer therapy.

Main Methods:

  • Review of current literature on adenosine metabolism in cancer.
  • Analysis of the role of ectonucleotidases (CD73, CD39) in immune suppression.
  • Examination of the impact of extracellular ATP conversion to adenosine.

Main Results:

  • Ectonucleotidases CD73 and CD39 are frequently expressed by various cells in the tumor microenvironment.
  • These enzymes convert extracellular ATP released by dying cells into adenosine.
  • Adenosine accumulation leads to the suppression of anti-tumor T cell responses.

Conclusions:

  • Targeting adenosine generation by inhibiting ectonucleotidases is a promising strategy.
  • Inhibition may restore anti-tumor immune responses.
  • This approach could enhance the efficacy of existing anti-cancer therapies.

More Related Videos

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice08:30

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice

Published on: April 19, 2011

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...